Jul 16, 2024, 08:43 AM by

Avallano is launching ProtocolCopilot™, an innovative AI-driven clinical research protocol assistant designed to transform the way biopharmaceutical companies and clinical research sites manage and interact with complex clinical trial protocols.

Jul 16, 2024, 08:43 AM by

Optibrium, a leading developer of software and AI solutions for drug discovery and molecular design, today announced the appointment of James Halle as Chief Commercial Officer (CCO). James brings extensive software experience in the pharma industry and will guide the commercial success of the company.

Jul 16, 2024, 05:00 AM by User Not Found

Bio-IT World | Artificial intelligence (AI) is the new frontier in biomedical research, with large language models changing the way science is done from writing code and brainstorming research ideas to helping do research and conducting literature reviews. In some of its latest applications, generative AI has been used in designing molecules with insights produced at a scale and speed not possible with traditional deep learning methods alone.

Jul 12, 2024, 08:46 AM by

Jul 12, 2024, 05:00 AM by User Not Found

Bio-IT World | Training and validating intelligent automation systems for life sciences R&D purposes can undermine the business case. But the large language models (LLMs) used to power Generative AI (GenAI) is changing that and bolstering compliance, enabling on-the-fly data discovery, “in context” learning, and narrative extrapolation.

Jul 11, 2024, 07:44 AM by

Synexa Life Sciences has announced its enrolment in the My Green Lab Certification Program.

Jul 11, 2024, 07:44 AM by

Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announced a collaboration aimed at enhancing colorectal cancer (CRC) screening methods.

Jul 11, 2024, 07:44 AM by

https://www.zymoresearch.com/blogs/press-releases/omics-discovery-grant-launch Apply for Zymo Research's Omics Discovery Grant for cutting-edge RNA-Seq tools worth $4000.

Jul 10, 2024, 06:48 AM by

SMi Systems announces the appointment of Dr Stefan Hamill as its Vice President of Strategy. Dr Hamill was formerly a senior analyst at investment banks Numis (now Deutsche Numis) and Peel Hunt, both of which he helped transform into #1 ranked franchises in UK Life Sciences.

Jul 10, 2024, 06:48 AM by

The first-of-its-kind collaboration combines personalized genetic insights with evidence-based treatments to provide accessible and effective obesity care for women

Jul 10, 2024, 06:48 AM by

Jul 10, 2024, 06:48 AM by

DoseMe, a leading provider of model-informed precision dosing (MIPD), announced today it has earned certified status by HITRUST for information security. HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s DoseMeRX has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places DoseMe in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls. DoseMe remains the only model informed precision dosing platform to achieve the r2 Certification.

Jul 10, 2024, 06:48 AM by

Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access. One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments.

Jul 10, 2024, 05:00 AM by User Not Found

Bio-IT World | Until recently, all the available therapeutic options for treating Alzheimer’s disease were designed to reduce symptoms rather than address causes of the disease. But with two beta-amyloid antibodies now approved by the U.S. Food and Drug Administration, and tau-targeting agents in clinical trials, hopes are rising that Alzheimer’s progression can be delayed if not stopped.

Jul 9, 2024, 16:22 PM by User Not Found

Bio-IT World | Illumina has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. Fluent Biosciences is now a wholly owned subsidiary of Illumina and was acquired with cash on hand.

Jul 9, 2024, 05:00 AM by User Not Found

Bio-IT World | When Regeneron began exploring how to digitize scientific information in lab environments, IT engineers didn’t begin by brainstorming their own ideas. They began by shadowing scientists.

Jul 8, 2024, 08:37 AM by

Jul 8, 2024, 08:37 AM by

Jul 3, 2024, 07:13 AM by

Jul 3, 2024, 07:13 AM by

Optibrium announced the publication of a peer-reviewed study in Journal of Computer-Aided Molecular Design, ‘From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product’. The paper demonstrates the successful application of the QuanSA (Quantitative Surface-field Analysis) method, part of Optibrium’s BioPharmics platform for 3D molecular design, to accelerate the lead optimisation of a complex macrocyclic natural product during agrochemical development. By significantly reducing the number of synthetic steps required during optimisation, the study supports the commercial viability of complex macrocyclic compounds.